Reaffirming that race is a social, not a biological, construct, ASN remains committed to ensuring that racial and ethnic biases do not affect the diagnosis and treatment of kidney diseases.
On May 4, 2021, the American Society of Nephrology (ASN) provided input to the Agency for Healthcare Research and Quality (AHRQ) in response to a Request for Information (RFI) on the use of clinical algorithms that may introduce racial/ethnic bias.
Reaffirming that race is a social, not a biological, construct, ASN remains committed to ensuring that racial and ethnic biases do not affect the diagnosis and treatment of kidney diseases. As stated in a letter to ASN membership in March 2021, ASN asserts that 1) race modifiers should not be included in equations to estimate kidney function and 2) current race-based equations should be replaced by a suitable approach that is accurate, inclusive, and standardized in every
laboratory in the United States. Any such approach must not differentially introduce bias, inaccuracy, or inequalities.
Read ASN’s comments on each of the topics below.
- Use of Race in Estimated Glomerular Filtration Rate (eGFR)
- Development and Validation of eGFR Equations
- Estimated Impact of Race-based eGFR on Quality of Care, Clinical Outcomes, and Health Disparities
- Nephrology Professional Standards and Guidance
- Awareness of Race-based eGFR
- Updating eGFR Equations and Current Challenges
- Estimated Impact of KDRI on Quality of Care, Clinical Outcomes, and Health Disparities
© 2021 American Society of Nephrology | All Rights Reserved
Powered by: PubFactory